

Tae-Wook Chun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/73622/publications.pdf>

Version: 2024-02-01

118
papers

18,824
citations

19657

61
h-index

20961

115
g-index

122
all docs

122
docs citations

122
times ranked

12303
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	52
2	Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature, 2022, 606, 368-374.	27.8	75
3	Combination anti-HIV antibodies provide sustained virological suppression. Nature, 2022, 606, 375-381.	27.8	65
4	Early human B cell signatures of the primary antibody response to mRNA vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	17
5	Correlation Between TIGIT Expression on CD8+ T Cells and Higher Cytotoxic Capacity. Journal of Infectious Diseases, 2021, 224, 1599-1604.	4.0	13
6	Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria. Aids, 2021, 35, 2225-2227.	2.2	11
7	Prolonged Posttreatment Virologic Control and Complete Seroreversion After Advanced Human Immunodeficiency Virus-1 Infection. Open Forum Infectious Diseases, 2021, 8, ofaa613.	0.9	6
8	Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. Nature Medicine, 2021, 27, 1893-1898.	30.7	23
9	Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature, 2020, 585, 261-267.	27.8	245
10	Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 10688-10698.	7.1	34
11	HIV RNA Rebound in Seminal Plasma after Antiretroviral Treatment Interruption. Journal of Virology, 2020, 94, .	3.4	5
12	Kinetics of Plasma HIV Rebound in the Era of Modern Antiretroviral Therapy. Journal of Infectious Diseases, 2020, 222, 1655-1659.	4.0	19
13	Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates. Scientific Reports, 2019, 9, 14696.	3.3	30
14	An open-label phase 1 clinical trial of the anti- CD4 CD25 monoclonal antibody vedolizumab in HIV-infected individuals. Science Translational Medicine, 2019, 11, .	12.4	40
15	Durable Control of HIV Infection in the Absence of Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 2019, 322, 27.	7.4	15
16	Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption. New England Journal of Medicine, 2019, 380, 1535-1545.	27.0	35
17	Impact of Treatment Interruption on HIV Reservoirs and Lymphocyte Subsets in Individuals Who Initiated Antiretroviral Therapy During the Early Phase of Infection. Journal of Infectious Diseases, 2019, 220, 270-274.	4.0	11
18	Delayed gastrointestinal-associated lymphoid tissue reconstitution in duodenum compared with rectum in HIV-infected patients initiating antiretroviral therapy. Aids, 2019, 33, 2289-2298.	2.2	6

#	ARTICLE	IF	CITATIONS
19	Overexpression of T-bet in HIV infection is associated with accumulation of B cells outside germinal centers and poor affinity maturation. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	65
20	Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. <i>JCI Insight</i> , 2019, 4, .	5.0	25
21	Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. <i>Journal of Clinical Investigation</i> , 2019, 129, 988-998.	8.2	209
22	Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals. <i>Journal of Clinical Investigation</i> , 2019, 129, 4832-4837.	8.2	11
23	Analytical treatment interruption in HIV-infected individuals: clinical perspectives. <i>Future Virology</i> , 2018, 13, 719-726.	1.8	0
24	Conflicting evidence for HIV enrichment in CD32+ CD4 T cells. <i>Nature</i> , 2018, 561, E9-E16.	27.8	40
25	Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4+ T Cells. <i>Immunity</i> , 2018, 48, 1183-1194.e5.	14.3	109
26	HIV-1 targets L-selectin for adhesion and induces its shedding for viral release. <i>Nature Communications</i> , 2018, 9, 2825.	12.8	15
27	IgG3 regulates tissue-like memory B cells in HIV-infected individuals. <i>Nature Immunology</i> , 2018, 19, 1001-1012.	14.5	27
28	The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. <i>Journal of Infectious Diseases</i> , 2018, 218, 1954-1963.	4.0	130
29	Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals. <i>PLoS Pathogens</i> , 2018, 14, e1006792.	4.7	74
30	Early antibody therapy can induce long-lasting immunity to SHIV. <i>Nature</i> , 2017, 543, 559-563.	27.8	244
31	Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 216, 813-818.	4.0	12
32	A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	105
33	In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication. <i>PLoS Pathogens</i> , 2017, 13, e1006575.	4.7	73
34	Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study. <i>PLoS Medicine</i> , 2017, 14, e1002461.	8.4	50
35	Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Na ⁺ ve to Antiretroviral Therapy: A Pilot Randomized Trial. <i>PLoS Pathogens</i> , 2016, 12, e1005381.	4.7	37
36	A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned. <i>BioResearch Open Access</i> , 2016, 5, 15-21.	2.6	5

#	ARTICLE	IF	CITATIONS
37	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. <i>New England Journal of Medicine</i> , 2016, 375, 2037-2050.	27.0	391
38	Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral Burdens. <i>Journal of Infectious Diseases</i> , 2016, 214, 390-398.	4.0	43
39	Maturation characteristics of HIV-specific antibodies in viremic individuals. <i>JCI Insight</i> , 2016, 1, .	5.0	42
40	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. <i>Science Translational Medicine</i> , 2015, 7, 319ra206.	12.4	390
41	Bone Marrow Plasma Cells Are a Primary Source of Serum HIV-1-Specific Antibodies in Chronically Infected Individuals. <i>Journal of Immunology</i> , 2015, 194, 2561-2568.	0.8	13
42	HIV reservoirs as obstacles and opportunities for an HIV cure. <i>Nature Immunology</i> , 2015, 16, 584-589.	14.5	200
43	Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals. <i>Journal of Clinical Investigation</i> , 2014, 124, 3252-3262.	8.2	130
44	HIV Type 1 (HIV-1) Proviral Reservoirs Decay Continuously Under Sustained Virologic Control in HIV-1-Infected Children Who Received Early Treatment. <i>Journal of Infectious Diseases</i> , 2014, 210, 1529-1538.	4.0	123
45	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 514-518.	2.1	13
46	CXCR4/IgG-expressing plasma cells are associated with human gastrointestinal tissue inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1676-1685.e5.	2.9	20
47	Glycosylation, Hypogammaglobulinemia, and Resistance to Viral Infections. <i>New England Journal of Medicine</i> , 2014, 370, 1615-1625.	27.0	117
48	Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 13151-13156.	7.1	72
49	Quantification of plasma HIV RNA using chemically engineered peptide nucleic acids. <i>Nature Communications</i> , 2014, 5, 5079.	12.8	30
50	Early Initiation of Combination Antiretroviral Therapy in HIV-1-Infected Newborns Can Achieve Sustained Virologic Suppression With Low Frequency of CD4+ T Cells Carrying HIV in Peripheral Blood. <i>Clinical Infectious Diseases</i> , 2014, 59, 1012-1019.	5.8	77
51	Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11698-11703.	7.1	130
52	Absence of Detectable HIV-1 Viremia after Treatment Cessation in an Infant. <i>New England Journal of Medicine</i> , 2013, 369, 1828-1835.	27.0	520
53	Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient. <i>PLoS Pathogens</i> , 2013, 9, e1003347.	4.7	244
54	Characterization of Plasmablasts in the Blood of HIV-Infected Viremic Individuals: Evidence for Nonspecific Immune Activation. <i>Journal of Virology</i> , 2013, 87, 5800-5811.	3.4	57

#	ARTICLE	IF	CITATIONS
55	Tracking replication-competent HIV reservoirs in infected individuals. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 111-116.	3.8	17
56	Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers. <i>Journal of Infectious Diseases</i> , 2013, 208, 1443-1447.	4.0	56
57	Viral Persistence in HIV Infection: Much Known, Much to Learn. <i>Journal of Infectious Diseases</i> , 2013, 208, 1356-1358.	4.0	6
58	Effect of Histone Deacetylase Inhibitors on HIV Production in Latently Infected, Resting CD4+ T Cells From Infected Individuals Receiving Effective Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2012, 206, 765-769.	4.0	83
59	Short Communication: HIV Type 1 Accumulates in Influenza-Specific T Cells in Subjects Receiving Seasonal Vaccination in the Context of Effective Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1687-1692.	1.1	13
60	HIV reservoirs. <i>Aids</i> , 2012, 26, 1261-1268.	2.2	151
61	Comprehensive analysis of unique cases with extraordinary control over HIV replication. <i>Blood</i> , 2012, 119, 4645-4655.	1.4	86
62	Humans with chronic granulomatous disease maintain humoral immunologic memory despite low frequencies of circulating memory B cells. <i>Blood</i> , 2012, 120, 4850-4858.	1.4	31
63	Paucity of HIV DNA Methylation in Latently Infected, Resting CD4 ⁺ T Cells from Infected Individuals Receiving Antiretroviral Therapy. <i>Journal of Virology</i> , 2012, 86, 5390-5392.	3.4	79
64	Towards an HIV cure: a global scientific strategy. <i>Nature Reviews Immunology</i> , 2012, 12, 607-614.	22.7	485
65	Towards a cure for HIV: a long road ahead. <i>Retrovirology</i> , 2012, 9, .	2.0	1
66	Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. <i>Aids</i> , 2011, 25, 741-749.	2.2	126
67	Authors' reply to correspondence by Le and Farrar. <i>Aids</i> , 2011, 25, 872-873.	2.2	2
68	Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. <i>Aids</i> , 2011, 25, 295-302.	2.2	25
69	Pathogenic Mechanisms of HIV Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2011, 6, 223-248.	22.4	312
70	Relationship Between Residual Plasma Viremia and the Size of HIV Proviral DNA Reservoirs in Infected Individuals Receiving Effective Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 135-138.	4.0	145
71	Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. <i>Journal of Clinical Investigation</i> , 2011, 121, 2614-2624.	8.2	121
72	Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. <i>Aids</i> , 2010, 24, 2803-2808.	2.2	233

#	ARTICLE	IF	CITATIONS
73	B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. <i>Blood</i> , 2010, 116, 5571-5579.	1.4	234
74	HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals. <i>Science</i> , 2010, 329, 174-180.	12.6	274
75	Evaluation of the Pathogenesis of Decreasing CD4+T Cell Counts in Human Immunodeficiency Virus Type 1-Infected Patients Receiving Successfully Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2009, 199, 1648-1656.	4.0	27
76	High frequencies of resting CD4 ⁺ T cells containing integrated viral DNA are found in rhesus macaques during acute lentivirus infections. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8015-8020.	7.1	45
77	Normalization of B Cell Counts and Subpopulations after Antiretroviral Therapy in Chronic HIV Disease. <i>Journal of Infectious Diseases</i> , 2008, 197, 572-579.	4.0	128
78	Persistence of HIV in Gut-Associated Lymphoid Tissue despite Long-Term Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2008, 197, 714-720.	4.0	489
79	Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. <i>Journal of Experimental Medicine</i> , 2008, 205, 1797-1805.	8.5	782
80	Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2008, 205, 2763-2779.	8.5	681
81	Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. <i>Journal of Cell Biology</i> , 2008, 183, i9-i9.	5.2	0
82	Decay of the HIV Reservoir in Patients Receiving Antiretroviral Therapy for Extended Periods: Implications for Eradication of Virus. <i>Journal of Infectious Diseases</i> , 2007, 195, 1762-1764.	4.0	180
83	Role for CD21 in the Establishment of an Extracellular HIV Reservoir in Lymphoid Tissues. <i>Journal of Immunology</i> , 2007, 178, 6968-6974.	0.8	32
84	Structural and Functional Characterization of CC Chemokine CCL14. <i>Biochemistry</i> , 2007, 46, 10008-10015.	2.5	37
85	Impact of HIV on Cell Survival and Antiviral Activity of Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2007, 2, e458.	2.5	68
86	Two overrepresented B cell populations in HIV-infected individuals undergo apoptosis by different mechanisms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 19436-19441.	7.1	73
87	Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: Correlation with increased IL-7. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2262-2267.	7.1	180
88	HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. <i>Journal of Clinical Investigation</i> , 2005, 115, 3250-3255.	8.2	246
89	Relationship between the frequency of HIV-specific CD8 ⁺ T cells and the level of CD38 ⁺ CD8 ⁺ T cells in untreated HIV-infected individuals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 2464-2469.	7.1	55
90	Decreased Survival of B Cells of HIV-viremic Patients Mediated by Altered Expression of Receptors of the TNF Superfamily. <i>Journal of Experimental Medicine</i> , 2004, 200, 587-600.	8.5	211

#	ARTICLE	IF	CITATIONS
91	Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. <i>Journal of Experimental Medicine</i> , 2004, 200, 587-99.	8.5	38
92	Innate Immunity in Human Immunodeficiency Virus Infection: Effect of Viremia on Natural Killer Cell Function. <i>Journal of Infectious Diseases</i> , 2003, 187, 1038-1045.	4.0	151
93	Rational Design of Drugs That Induce Human Immunodeficiency Virus Replication. <i>Journal of Virology</i> , 2003, 77, 10227-10236.	3.4	44
94	Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 6057-6062.	7.1	73
95	Deleterious Effect of HIV-1 Plasma Viremia on B Cell Costimulatory Function. <i>Journal of Immunology</i> , 2003, 170, 5965-5972.	0.8	95
96	Genetic Characterization of Rebounding Human Immunodeficiency Virus Type 1 in Plasma during Multiple Interruptions of Highly Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2003, 77, 3229-3237.	3.4	42
97	Gene expression and viral production in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 1908-1913.	7.1	174
98	Continuous flow leukapheresis induces expression of stress genes in lymphocytes: impact on microarray analyses. <i>Blood</i> , 2003, 102, 3852-3853.	1.4	8
99	Relationship between the Size of the Human Immunodeficiency Virus Type 1 (HIV-1) Reservoir in Peripheral Blood CD4+ T Cells and CD4+:CD8+ T Cell Ratios in Aviremic HIV-1 Infected Individuals Receiving Long-Term Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2002, 185, 1672-1676.	4.0	122
100	Biochemical and Biological Characterization of a Dodecameric CD4-Ig Fusion Protein. <i>Journal of Biological Chemistry</i> , 2002, 277, 11456-11464.	3.4	71
101	Human Immunodeficiency Virus Type 1 Bound to B Cells: Relationship to Virus Replicating in CD4+ T Cells and Circulating in Plasma. <i>Journal of Virology</i> , 2002, 76, 8855-8863.	3.4	36
102	Pilot Study of the Effects of Intermittent Interleukin-2 on Human Immunodeficiency Virus (HIV)-Specific Immune Responses in Patients Treated during Recently Acquired HIV Infection. <i>Journal of Infectious Diseases</i> , 2002, 185, 61-8.	4.0	86
103	Detection of HIV DNA and RNA Using PCR. <i>Current Protocols in Immunology</i> , 2001, 42, Unit 12.6.	3.6	1
104	Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. <i>Nature Medicine</i> , 2001, 7, 1225-1231.	30.7	73
105	395 The effect of elective C-section, preterm labor and chorioamnionitis on fetal lymphocyte activation and susceptibility to HIV infection. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 185, S189.	1.3	0
106	Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: Implications for the development of therapeutic strategies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 253-258.	7.1	74
107	Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. <i>Nature Medicine</i> , 2000, 6, 757-761.	30.7	404
108	B Cells of HIV-1 Infected Patients Bind Virions through Cd21 Complement Interactions and Transmit Infectious Virus to Activated T Cells. <i>Journal of Experimental Medicine</i> , 2000, 192, 637-646.	8.5	178

#	ARTICLE	IF	CITATIONS
109	Latent reservoirs of HIV: Obstacles to the eradication of virus. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 10958-10961.	7.1	317
110	Re-emergence of HIV after stopping therapy. Nature, 1999, 401, 874-875.	27.8	390
111	Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nature Medicine, 1999, 5, 651-655.	30.7	400
112	CD40-Mediated Induction of CD4 and CXCR4 on B Lymphocytes Correlates with Restricted Susceptibility to Human Immunodeficiency Virus Type 1 Infection: Potential Role of B Lymphocytes as a Viral Reservoir. Journal of Virology, 1999, 73, 7972-7980.	3.4	61
113	Both Memory and CD45RA ⁺ /CD62L ⁺ Naive CD4 ⁺ T Cells Are Infected in Human Immunodeficiency Virus Type 1-Infected Individuals. Journal of Virology, 1999, 73, 6430-6435.	3.4	200
114	Induction of HIV-1 Replication in Latently Infected CD4+ T Cells Using a Combination of Cytokines. Journal of Experimental Medicine, 1998, 188, 83-91.	8.5	344
115	Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 8869-8873.	7.1	764
116	Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 13193-13197.	7.1	1,786
117	Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature, 1997, 387, 183-188.	27.8	1,921
118	In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency. Nature Medicine, 1995, 1, 1284-1290.	30.7	709